Streetbeat News

GNPX

Genprex, Inc.

https://www.genprex.com

Industry

Biotechnology

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Open

1.10

Mkt cap

9.7M

Volume

739K

High

1.20

P/E Ratio

-0.11

52-wk high

14.40

Low

1.08

Div yield

N/A

52-wk low

0.28

Genprex, Inc. has signed an exclusive license agreement with the University of Michigan for gene therapy technologies aimed at treating ALK-positive lung cancer. This includes the use of Genprex's Reqorsa® Gene Therapy in combination with ALK-inhibitors.

Portfolio Pulse from

November 20, 2024 | 2:45 pm

In Monday's after-market session, Shuttle Pharmaceuticals, Impact BioMedical, and Onconetix saw significant stock price increases, while TransMedics Group and Cardio Diagnostics Holdings experienced notable declines. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 8:31 pm

Genprex shares rose following the presentation of preclinical data on Reqorsa Gene Therapy, Mesothelioma, and Glioblastoma at the 2024 EORTC-NCI-AACR Symposium.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 4:31 pm

Several healthcare stocks experienced significant price movements during Monday's intraday session. Notable gainers included Healthcare Triangle, Monte Rosa Therapeutics, and Evoke Pharma, while Sonnet BioTherapeutics and Koninklijke Philips were among the losers. The movements were influenced by various factors, including earnings reports.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 4:30 pm

Genprex's short interest has increased by 5.38%, with 85,000 shares sold short, representing 3.33% of its float. This is below the peer group average of 3.81%. Short interest can indicate market sentiment, with rising short interest suggesting bearish sentiment.

Portfolio Pulse from Benzinga Insights

October 28, 2024 | 3:30 pm

Genprex presented preclinical data on its Reqorsa gene therapy for lung cancer, mesothelioma, and glioblastoma at the 2024 EORTC-NCI-AACR Symposium.

Portfolio Pulse from Benzinga Newsdesk

October 28, 2024 | 1:31 pm

Genprex, Inc. has entered into a Sponsored Research Agreement with the University of Michigan Rogel Cancer Center to study the TUSC2 gene in combination with ALK-inhibitors for lung cancer treatment. This collaboration could expand the potential patient population for Genprex's Reqorsa Gene Therapy.

Portfolio Pulse from Benzinga Newsdesk

October 24, 2024 | 1:32 pm

In Thursday's pre-market session, several healthcare stocks experienced significant movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

In Thursday's pre-market session, several health care stocks experienced significant price movements. Notable gainers included Tevogen Bio Holdings, CNS Pharma, and DBV Technologies, while Conduit Pharmaceuticals, Genprex, and Ensysce Biosciences were among the losers.

Portfolio Pulse from Benzinga Insights

October 24, 2024 | 12:07 pm

In Wednesday's pre-market session, several healthcare stocks experienced significant price movements. CNS Pharma, DBV Technologies, and Cyclacel Pharmaceuticals were among the top gainers, while Alto Neuroscience and Ensysce Biosciences saw notable declines.

Portfolio Pulse from Benzinga Insights

October 23, 2024 | 12:08 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.